Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.58 |
| ▸ | PPARA | Q07869 | 9/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.45 |
| ▸ | FNTB | P49356 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL934313 | 0.92 | PPARG (0.61) | PPARGPPARAPOLBMEN1CASP3 | |
| SCHEMBL934527 | 0.87 | PPARG (0.55) | PPARGPPARAPOLBCNR2MEN1 | |
| SCHEMBL11566109 | 0.87 | PPARG (0.57) | PPARGPPARAPOLBMEN1CASP3 | |
| SCHEMBL11577623 | 0.85 | NPSR1 (0.52) | PPARGPPARAMEN1KMT2A | |
| SCHEMBL8935861 | 0.85 | KDM4E (0.52) | PPARGPPARAMEN1KMT2A | |
| SCHEMBL11752505 | 0.85 | PPARG (0.67) | PPARGPPARAPOLBMEN1CASP3 | |
| SCHEMBL21881525 | 0.85 | PPARG (0.59) | PPARGPPARAPOLBMEN1CASP3 | |
| SCHEMBL8935862 | 0.85 | KDM4E (0.52) | PPARGPPARAMEN1KMT2A | |
| SCHEMBL14889080 | 0.85 | PPARG (0.67) | PPARGPPARAPOLBMEN1CASP3 | |
| SCHEMBL6005316 | 0.85 | PPARG (0.59) | PPARGPPARAPOLBMEN1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088800-A1 | 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS | ALLERGAN, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| EP-2305648-A1 | Amide derivatives useful as glucokinase activators | Novo Nordisk A/S (DK) | 2011-04-06 | — | — | EP | disclosed |
| WO-2011008475-A1 | OPTIONALLY SUBSTITUTED 2-(ARYLMETHYL, ARYLOXY OR ARYLTHIO) -N- PYRIDIN-2 -YL-ARYL ACETAMIDE OR 2, 2-BIS (ARYL) -N-PYRIDIN-2-YL ACETAMIDE COMPOUNDS AS MEDICAMENTS FOR THE TREATMENT OF EYE DISEASES | ALLERGAN, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| CN-100506807-C | Amide derivatives as GK activators | NOVO NORDISK AS (DK) | 2009-07-01 | — | — | CN | disclosed |
| CN-101434585-A | Amide derivatives as GK activators | NOVO NORDISK AS (DK) | 2009-05-20 | — | — | CN | disclosed |
| CN-1658871-A | Amide derivatives as GK activators | NOVO NORDISK AS (DK) | 2005-08-24 | — | — | CN | disclosed |
| EP-1458382-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| US-20030171411-A1 | Amide derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2003-09-11 | — | — | US | disclosed |
| EP-1336607-A1 | Amide derivatives as glucokinase activators | NOVO NORDISK A/S (DK) | 2003-08-20 | — | — | EP | disclosed |
| WO-2003055482-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088800-A1 | 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS | S1PR3, S1PR5, S1PR1 | PPARG 287/4885PPARA 369/4885POLB 4030/4885 |
| US-20030171411-A1 | Amide derivatives as therapeutic agents | GK, GCKR, GCK | PPARG 75/4885PPARA 303/4885POLB 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.